Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03302637 · ClinicalTrials.gov registry record
Oral Microbiome and Pancreatic Cancer
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 732
- Enrollment target
NCT03302637 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 732 participants.
The verdict
NCT03302637 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 732 participants
- Enrollment target
Study Summary
This is a prospective population based study to examine the relationship of oral and pancreatic microbiome, and their functions, to pancreatic cancer risk. The identification of specific oral bacteria and their functional relationship to pancreatic cancer will advance scientific knowledge on the etiology of pancreatic cancer. This could provide a new microbially-based research paradigm, possibly leading to new drug targets for this disease. Second, the oral bacteria may serve as a readily accessible, non-invasive biomarker for subsequent pancreatic cancer risk, which help to identify people at high risk of this disease. Finally, the identified oral bacteria may lead to microbial prophylactic preventions, with antibiotic therapy aimed at eradicating the specific species associated with increased cancer risk or, alternatively, combined with probiotics to introduce species that are associated with a decreased cancer risk. Thus, the study outcomes will lead to actionable means for pancreatic cancer prevention.
Interventions
- OTHER 16S rRNA gene sequencing assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 732 participants |
| Start Date | 1992-12-01 |
| Est. Completion | 2010-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03302637
The ClinicalTrials.gov registry entry for NCT03302637 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 732 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 16S rRNA gene sequencing assay is the first listed.
NCT03302637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03302637 about?
NCT03302637 is a clinical study titled "Oral Microbiome and Pancreatic Cancer". This is a prospective population based study to examine the relationship of oral and pancreatic microbiome, and their functions, to pancreatic cancer risk. The identification of specific oral bacteria and their functional relationship to pancreatic cancer will advance scientific knowledge on the et...
What is the current status of trial NCT03302637?
This trial is currently completed. The enrollment target is 732 participants. The study started on 1992-12-01. Estimated completion is 2010-12-01.
What interventions are being tested in trial NCT03302637?
The interventions under investigation include: 16S rRNA gene sequencing assay (OTHER).
Who is sponsoring clinical trial NCT03302637?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.